Arrivo BioVentures’ SIRT6 activator SP-624 has been found to significantly reduce symptoms of major depressive disorder (MDD), but only in women. Steve Butts, Arrivo CEO, stated that data from a Phase ...
In the search for ways to effectively combat age-related human disease, the enzyme sirtuin 6 (Sirt6) has recently become a focus of biochemical research. A targeted activation of Sirt6 could prevent ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 ...
In the search for ways to effectively combat age-related human disease, the enzyme sirtuin 6 (Sirt6) has recently become a focus of biochemical research. A targeted activation of Sirt6 could prevent ...
Why is age the strongest risk factor for Alzheimer’s disease? In the December 10 Science Signaling, scientists led by Ning Bai, Difei Wang, Yu Di, and Liu Cao at China Medical University in Shenyang, ...
Researchers at Bar-Ilan University have successfully restored youthful patterns of DNA organization in the livers of old mice, reversing key molecular features associated with aging. The study, ...
Please provide your email address to receive an email when new articles are posted on . The clinical trial of SP-624 is expected to enroll 450 patients with major depressive disorder. The primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results